SubsidieMeestersThe development of a predictive biomarker for immunotherapy outcome based on flow cytometry test
The project aims to develop a flow cytometry-based predictive biomarker for immunotherapy response, enhancing personalized treatment and aiding pharmaceutical R&D through the detection of immunotherapy-responsiveness cells (IRCs).
Projectdetails
Introduction
Immunotherapy has revolutionised clinical oncology, with the use of immune checkpoint inhibitors (ICIs). These agents have been in clinical use for almost a decade, treating over 20 types of cancers. They have shown a remarkable therapeutic benefit even in patients with advanced disease.
Current Challenges
Yet, only a small proportion of patients benefit from this therapy, leaving the rest resistant for reasons that are still not clear. While there are certain clinical biomarkers to predict ICI therapy outcomes, their prevalence and predictive power are rather limited. Therefore, there is a clinical unmet need to develop more powerful biomarkers to predict response to immunotherapy.
Discovery of IRCs
In our ongoing ERC consolidator grant, we discovered a unique sub-population of neutrophils, present in peripheral blood, that predicts response to immunotherapy with a very high probability. We designated these cells as immunotherapy-responsiveness cells (IRCs).
Research Findings
Using various mouse models, we demonstrate that the levels of circulating IRCs measured at baseline are significantly higher in responding tumours to ICI therapy. These results were confirmed in a limited number of non-small cell lung cancer (NSCLC) and melanoma patients.
Future Aims
Hence, our aim is to further test IRC levels in clinical samples to evaluate their predictive power for ICI therapy. Additionally, we plan to develop a clinical liquid biopsy-based predictive biomarker using a flow cytometry test.
Market Potential
The development of clinical IRC detection based on flow cytometry (BioFlow®) can serve two markets:
- Clinicians – enabling oncologists to easily predict response to ICI therapy, thus improving personalised immunotherapy treatment.
- Pharmaceutical companies - developing immunotherapies that can use IRC detection in development stages and through clinical studies, enabling tight regulative assessment of R&D success rates.
Conclusion
The BioFlow goal is to technically validate and develop a predictive biomarker platform for both markets that will lead to its commercialisation.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 150.000 |
| Totale projectbegroting | € 150.000 |
Tijdlijn
| Startdatum | 1-9-2022 |
| Einddatum | 29-2-2024 |
| Subsidiejaar | 2022 |
Partners & Locaties
Projectpartners
- TECHNION - ISRAEL INSTITUTE OF TECHNOLOGYpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
MANUNKIND: Determinants and Dynamics of Collaborative ExploitationThis project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery. | ERC STG | € 1.497.749 | 2022 | Details |
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressureThe UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance. | ERC STG | € 1.498.280 | 2022 | Details |
Uncovering the mechanisms of action of an antiviral bacteriumThis project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function. | ERC STG | € 1.500.000 | 2023 | Details |
The Ethics of Loneliness and SociabilityThis project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field. | ERC STG | € 1.025.860 | 2023 | Details |
MANUNKIND: Determinants and Dynamics of Collaborative Exploitation
This project aims to develop a game theoretic framework to analyze the psychological and strategic dynamics of collaborative exploitation, informing policies to combat modern slavery.
Elucidating the phenotypic convergence of proliferation reduction under growth-induced pressure
The UnderPressure project aims to investigate how mechanical constraints from 3D crowding affect cell proliferation and signaling in various organisms, with potential applications in reducing cancer chemoresistance.
Uncovering the mechanisms of action of an antiviral bacterium
This project aims to uncover the mechanisms behind Wolbachia's antiviral protection in insects and develop tools for studying symbiont gene function.
The Ethics of Loneliness and Sociability
This project aims to develop a normative theory of loneliness by analyzing ethical responsibilities of individuals and societies to prevent and alleviate loneliness, establishing a new philosophical sub-field.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors. | EIC Accelerator | € 2.496.112 | 2024 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
canceR agnOstic immUnoTherapy predIctioN blood-tEstPamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment. | EIC Accelerator | € 2.500.000 | 2023 | Details |
Trial BoosterVitroScan en Imuno ontwikkelen een screeningsplatform om de effectiviteit van immuuntherapie bij blaaskanker te voorspellen, waardoor patiëntselectie voor klinische studies verbetert. | MIT R&D Samenwerking | € 347.410 | 2022 | Details |
IOO: a novel assay to predict patient response to immune checkpoint inhibitors, optimising patient stratification to these therapies and tripling solid tumour patient outcomes in immuno-oncology.
The project aims to enhance cancer immunotherapy efficacy by developing a validated biomarker assay to predict patient responses, potentially doubling survival rates for lethal tumors.
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samples
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
canceR agnOstic immUnoTherapy predIctioN blood-tEst
PamGene's IOpener is an innovative diagnostic platform that predicts immune checkpoint inhibitor response from a blood sample, aiming to enhance precision medicine in cancer treatment.
Trial Booster
VitroScan en Imuno ontwikkelen een screeningsplatform om de effectiviteit van immuuntherapie bij blaaskanker te voorspellen, waardoor patiëntselectie voor klinische studies verbetert.